Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + butalbital + caffeine + codeine
- Development stage
- Unknown
- Lead developer
- Sandoz
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aspirin + butalbital + caffeine + codeine is an oral fixed-dose **small molecule combination** analgesic containing aspirin, butalbital, caffeine, and codeine phosphate. It is FDA-approved in capsule form for the management of the symptom complex of **tension headache** or **muscle contraction headache** when non-opioid analgesics and alternative treatments are inadequate. The combination pairs aspirin-mediated cyclooxygenase inhibition with barbiturate sedative effects from butalbital, adenosine receptor antagonism and analgesic adjuvant activity from caffeine, and opioid receptor agonism from codeine. Marketed in the United States under brand names including Ascomp with Codeine, Fiorinal with Codeine, and Fiortal with Codeine, it is reserved for patients who have not responded adequately to other options because of risks including addiction, abuse, misuse, overdose, and life-threatening respiratory depression related mainly to the butalbital and codeine components.
- Brand names
- Ascomp with CodeineFiorinal with CodeineFiortal with Codeine
- Other names
- butalbital + aspirin + caffeine + codeine phosphatebutalbital, aspirin, caffeine, and codeine phosphate capsulesbutalbital aspirin caffeine and codeine phosphate
02
Targets
ADORA2A (Adenosine A₂A Receptor)GABRR (GABA-A receptor subunit rho)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ADORA1 (Adenosine receptor A1 subtype)MOR (Mu opioid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on aspirin + butalbital + caffeine + codeine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + butalbital + caffeine + codeine.